Abstract
Severe corticosteroid-refractory graft-versus-host-disease (GVHD) is a major non-relapse cause of mortality and morbidity after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). One of the most promising treatment options is using advanced therapy medicinal products based on mesenchymal stem cells (MSCs) immunomodulation ability. The protocols of MSC application differ in many parameters including a source of MSC, a dose, a number of doses or way of preparation of the medicinal product. The process is limited by the need for laborious and expensive manufacturing processes fraught with batch-to-batch variability. In our study, we compared the immunomodulatory effects of different MSC batches versus pooled MSC, specifically the influence on lymphocyte proliferation, the metabolic activity, and the expression of activation markers on T cells. Our goal was to determine whether the effect depends on donor-to-donor heterogeneity and if pooling of MSCs could increase their immunomodulatory ability. All tested batches showed an immunomodulatory effect, with no significant differences between the groups. Our study suggests that immunosuppressive potential is comparable in single batches and pooled products, and the use of products got from individual donors is suitable to treat corticosteroid-refractory GVHD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adak S, Mukherjee S, Sen D (2017) Mesenchymal stem cell as a potential therapeutic for inflammatory bowel disease- myth or reality? Curr Stem Cell Res Ther 12:644–657. https://doi.org/10.2174/1574888X12666170914113633
Amati E, Sella S, Perbellini O et al (2017) Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use. Stem Cell Res Ther 8:14. https://doi.org/10.1186/s13287-016-0465-2
Apostolova P, Zeiser R (2016) The role of purine metabolites as DAMPs in acute graft-versus-host disease. Front Immunol 7:439. https://doi.org/10.3389/fimmu.2016.00439
Arima N, Nakamura F, Fukunaga A et al (2010) Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Cytotherapy 12:265–268. https://doi.org/10.3109/14653240903390795
Bader AM, Brodarac A, Klose K et al (2014) Mechanisms of paracrine cardioprotection by cord blood mesenchymal stromal cells. Eur J Cardiothorac Surg 45:983–992. https://doi.org/10.1093/ejcts/ezt576
Ball LM, Bernardo ME, Roelofs H et al (2013) Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol 163:501–509. https://doi.org/10.1111/bjh.12545
Brychtova M, Thiele J-A, Lysak D et al (2018) Mesenchymal stem cells as the near future of cardiology medicine—truth or wish? Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov. https://doi.org/10.5507/bp.2018.071
Castro-Manrreza ME, Montesinos JJ (2015) Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015:394917. https://doi.org/10.1155/2015/394917
Chiesa S, Morbelli S, Morando S et al (2011) Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 108:17384–17389. https://doi.org/10.1073/pnas.1103650108
Cho J, D’Antuono M, Glicksman M et al (2018) A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus. Am J Stem Cells 7:82–93
Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372. https://doi.org/10.1182/blood-2005-07-2657
Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International society for cellular therapy position statement. Cytotherapy 8:315–317. https://doi.org/10.1080/14653240600855905
Gao F, Chiu SM, Motan DAL et al (2016) Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 7:e2062. https://doi.org/10.1038/cddis.2015.327
Glennie S, Soeiro I, Dyson PJ et al (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821–2827. https://doi.org/10.1182/blood-2004-09-3696
Hoogduijn MJ, Popp F, Verbeek R et al (2010) The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 10:1496–1500. https://doi.org/10.1016/j.intimp.2010.06.019
Introna M, Lucchini G, Dander E et al (2014) Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 20:375–381. https://doi.org/10.1016/j.bbmt.2013.11.033
Kuçi Z, Bönig H, Kreyenberg H et al (2016) Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica 101:985–994. https://doi.org/10.3324/haematol.2015.140368
Lai P, Chen X, Guo L et al (2018) A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol. https://doi.org/10.1186/s13045-018-0680-7
Le Blanc K, Ringdén O (2007) Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262:509–525. https://doi.org/10.1111/j.1365-2796.2007.01844.x
Le Blanc K, Rasmusson I, Sundberg B et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet Lond Engl 363:1439–1441. https://doi.org/10.1016/S0140-6736(04)16104-7
Le Blanc K, Frassoni F, Ball L et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet Lond Engl 371:1579–1586. https://doi.org/10.1016/S0140-6736(08)60690-X
Luz-Crawford P, Kurte M, Bravo-Alegría J et al (2013) Mesenchymal stem cells generate a CD4 + CD25 + Foxp3 + regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 4:65. https://doi.org/10.1186/scrt216
Lysák D, Koutová L, Holubová M et al (2016) The quality control of mesenchymal stromal cells by in vitro testing of their immunomodulatory effect on allogeneic lymphocytes. Folia Biol (Praha) 62:120–130
McManigle W, Youssef A, Sarantopoulos S (2019) B cells in chronic graft-versus-host disease. Hum Immunol 80:393–399. https://doi.org/10.1016/j.humimm.2019.03.003
Mendicino M, Bailey AM, Wonnacott K et al (2014) MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 14:141–145. https://doi.org/10.1016/j.stem.2014.01.013
Munir H, Luu N-T, Clarke LSC et al (2016) Comparative ability of mesenchymal stromal cells from different tissues to limit neutrophil recruitment to inflamed endothelium. PLoS ONE 11:e0155161. https://doi.org/10.1371/journal.pone.0155161
Munneke JM, Spruit MJ, Cornelissen AS et al (2016) The potential of mesenchymal stromal cells as treatment for severe steroid-refractory acute graft-versus-host disease: a critical review of the literature. Transplantation 100:2309–2314. https://doi.org/10.1097/TP.0000000000001029
Muroi K, Miyamura K, Okada M et al (2016) Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol 103:243–250. https://doi.org/10.1007/s12185-015-1915-9
Pérez-Simon JA, López-Villar O, Andreu EJ et al (2011) Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 96:1072–1076. https://doi.org/10.3324/haematol.2010.038356
Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells Dayt Ohio 25:2896–2902. https://doi.org/10.1634/stemcells.2007-0637
Ringdén O, Uzunel M, Rasmusson I et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397. https://doi.org/10.1097/01.tp.0000214462.63943.14
Rizk M, Monaghan M, Shorr R et al (2016) Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 22:1416–1423. https://doi.org/10.1016/j.bbmt.2016.04.010
Stolzing A, Jones E, McGonagle D, Scutt A (2008) Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 129:163–173. https://doi.org/10.1016/j.mad.2007.12.002
Stoma I, Karpov I, Krivenko S et al (2018) Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. Ann Hematol 97:885–891. https://doi.org/10.1007/s00277-018-3250-8
von Bonin M, Kiani A, Platzbecker U et al (2009) Third-party mesenchymal stem cells as part of the management of graft-failure after haploidentical stem cell transplantation. Leuk Res 33:e215–e217. https://doi.org/10.1016/j.leukres.2009.05.023
Wagner W, Wein F, Seckinger A et al (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33:1402–1416. https://doi.org/10.1016/j.exphem.2005.07.003
Fan X-L, Zhang Z, Ma CY, Fu Q-L (2019) Mesenchymal stem cells for inflammatory airway disorders: promises and challenges. Biosci Rep. https://doi.org/10.1042/BSR20182160
Zahari W, Hashim SNM, Yusof MFH et al (2017) Immunomodulatory effect of cytokines in the differentiation of mesenchymal stem cells: a review. Curr Stem Cell Res Ther 12:197–206. https://doi.org/10.2174/1574888X11666160614103404
Zarei F, Abbaszadeh A (2018) Application of cell therapy for anti-aging facial skin. Curr Stem Cell Res Ther. https://doi.org/10.2174/1574888X13666181113113415
Zhao Q, Ren H, Han Z (2016) Mesenchymal stem cells: immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother 2:3–20. https://doi.org/10.1016/j.jocit.2014.12.001
Acknowledgments
This work was supported by the grant of the Ministry of Health of the Czech Republic – Conceptual Development of Research Organization (Faculty Hospital in Pilsen – FNPl, 00669806).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hejretová, L., Čedíková, M., Dolejšová, M. et al. Comparison of the immunomodulatory effect of single MSC batches versus pooled MSC products. Cell Tissue Bank 21, 119–129 (2020). https://doi.org/10.1007/s10561-019-09805-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-019-09805-3